ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

toripalimab

Also written as “Toripalimab”, “Toripalimab Injection” and “CM082 plus JS001”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Melanoma · Stomach Neoplasms · Carcinoma, Transitional Cell, led by 5 companies.

Drug pageToripalimab: every studyMany companies study it; this page follows only the 13 they lead. All 362 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Mar 17, 202213 company-led studies, 10 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
RemeGenits history only54 open or runningphase 2since Mar 17, 2022Mar 17, 2022none ahead
Mabwell (Shanghai) Bioscienceits history only33 open or runningphase 3since Sep 9, 2024Sep 25, 2023Dec 31, 2026phase 2 · NCT06079112
Coherus Oncologyits history only22 open or runningphase 4since Jun 10, 2024Jun 10, 2024Dec 2027phase 4 · NCT06457503
Suzhou Zelgen Biopharmaceuticalsits history only21 open or runningphase 2since Aug 3, 2020Aug 3, 2020none ahead
CSPC Pharmaceutical Group10 open or runningphase 3since Dec 12, 2018Dec 12, 2018none ahead

Also a collaborator on its studies: Medpace.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of CSPC Pharmaceutical Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2018Named toripalimabINNProposed as its International Nonproprietary Name in WHO's List 119 · before, JS001
  2. Dec 12, 2018First study: phase 3 study in Triple Negative Breast NeoplasmsFirst studyNCT03777579 · 375 enrolled · China

TargetBeta

PDCD1 →read by rule
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

The one study CSPC Pharmaceutical Group leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03777579Triple Negative Breast Neoplasms · China3SuspendedDec 30, 2019375

How it is read

Names in the registry

  • “Toripalimab”, 14 entries
  • “Toripalimab Injection”, 3 entries
  • “CM082 plus JS001”, 3 entries
  • “ABO2109 Injection;Toripalimab”, 2 entries
  • “JS001”, 2 entries

Codes read as this program: JS001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.